#1 New Genital Herpes Drug Proves More Promising Than Existing Treatment in Clinical Trial
As what may be one of the most promising treatments for the herpes simplex virus 2 (HSV-2) in two decades, pritelivir, has demonstrated in a recent trial that it provides greater viral suppression than the present standard treatment, valacyclovir.
In the study, conducted by a research team led by Anna Wald, MD, medical director of virology research at the University of Washington, Fred Hutchinson Cancer Research Center in Seattle, patients who took pritelivir not only experienced less HSV shedding than those who took valacyclovir (2.4% vs. 5.3%), but they also had fewer lesions (1.9% vs. 3.9%), less pain, and fewer treatment-emergent adverse events (62% vs. 69%).
Pritelivir, which is still in the relatively early stages of development, is particularly attractive to patients with HSV-2 (otherwise known as genital herpes) because it not only limits their symptoms, but also appears to reduce the likelihood of passing the infection on to a susceptible partner. Of note: pritelivir did not completely eliminate viral shedding; practitioners and patients must remember that the protection is only partial. Given that many infected individuals often do not show signs of infection but still shed viral cells intermittently, “management of genital HSV should address the chronic nature of the disease rather than focusing solely on treatment of acute episodes of genital lesions,” a CDC spokesperson also noted. The spokesperson added that HSV-2 infections tend to have “much more frequent” recurrences and shedding.
Continue reading the full article here
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.